SCHEMBL30451032

SCHEMBL30451032

CN(C)C(=O)c1ccc(OCCCCC2CCN(C(=O)c3c(F)cccc3F)CC2)nc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.41
FFAR4 Q5NUL3 3/20 0.38
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 1/20 0.36
HTR2A P28223 2/20 0.36
HTR2C P28335 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
HTR1A P08908 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20060865 1.00 GPR119 (0.41) GPR119FFAR4ABL1BCRKMT2A
SCHEMBL20060863 0.97 FFAR4 (0.38) GPR119FFAR4ABL1BCRKMT2A
SCHEMBL20061052 0.82 GPR119 (0.62) GPR119
SCHEMBL20060876 0.81 GPR119 (0.40) GPR119KMT2AGAASMN1; SMN2LMNA
SCHEMBL30451138 0.81 GPR119 (0.40) GPR119KMT2AGAASMN1; SMN2LMNA
SCHEMBL22284421 0.80 NR1H2 (0.54) GPR119FFAR4
SCHEMBL30451124 0.80 NR1H2 (0.54) GPR119FFAR4
SCHEMBL20060880 0.80 NR1H2 (0.54) GPR119FFAR4
SCHEMBL20060842 0.80 NR1H2 (0.54) GPR119FFAR4
SCHEMBL20060870 0.80 GPR119 (0.40) GPR119LMNADRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526196-B1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS MERCK SHARP & DOHME LLC (US) 2026-03-18 EP disclosed
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use MERCK SHARP & DOHME LLC (US) 2023-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use NR1H2, NR1H3, NR1H4 GPR119 15/4885FFAR4 94/4885ABL1 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.